P166 Budget impact of MammaPrint® in Patients with primary hormone receptor-positive, HER2-negative and non-metastatic early-stage breast cancer in France. (April 2023) - Zarca, D.; Delomenie, M.; Pujol, P.; Klinkhamer, J.; Cusumano, P.G.